Triple combination cures most hepatitis C patients with prior DAA treatment failure
Early ART highly acceptable and achieves excellent rates of viral suppression among young South African women
EASL releases updated hepatitis B guidelines at International Liver Congress
Switching to TAF for hepatitis B improves kidney function and bone loss
A quarter of people with second-line ART treatment failure in Kenya have exhausted current treatment options
Generic hepatitis C drugs continue to produce high cure rates
What women want – sexual and reproductive health rights
Switching from Atripla to generic-containing regimens can produce large cost savings
AbbVie combination cures 95% of genotype 3 hepatitis C
